Over the last five years, the industry has traded as high as 20.80X, as low as 12.92X and at a median of 15.13X, as the chart ... Humira, are declining due to loss of exclusivity and biosimilar ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Alvotech (NASDAQ: ALVO, or the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to ... Program together with adalimumab-aaty will help us ...

Number 3: Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab ...

REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in ...